The U.S. Food and Drug Administration (FDA) has given Daewoong Pharmaceutical the go-ahead to start a Phase 2 clinical trial to test the company’s experimental anti-fibrotic medication DWN12088 in people with idiopathic pulmonary fibrosis (IPF). “The existing treatments of Idiopathic pulmonary fibrosis still have high unmet medical needs.
Daewoong to Start Phase 2 Trial of DWN12088 in IPF Patients This Year
Participants in a Phase 2 trial testing Algernon Pharmaceuticals’ NP-120 (ifenprodil) in people with chronic cough associated with idiopathic pulmonary fibrosis (IPF) have asked to have the experimental medication for their personal use, Algernon announced. The company noted in a press release that it’s “not making any express or…
“I’m so busy” feels like it’s now a common response to the question, “How are you?” It’s like being busy is glorified or worn as a badge of honor among many of us, myself included. Living with idiopathic pulmonary fibrosis (IPF), a life-threatening and debilitating lung disease, has forced…
Cymerus mesenchymal stem cells (MSCs), Cynata Therapeutics’ experimental cell therapy, significantly lowered the levels of pro-inflammatory and pro-scarring molecules in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF), the company announced. The “highly potent” therapy also was shown to significantly reduce immune cell infiltration, and the…
Prior to my diagnosis of idiopathic pulmonary fibrosis in 2017, my day started the same way almost every morning. I’d pick up my smartphone and see how the markets performed overnight. Then I’d look for an expected opening, based on the overseas markets. Since my diagnosis, I no longer…
Mesenchymal stem cells (MSCs) grown in three-dimension (3D) conditions produce tiny extracellular vesicles (EVs) that do not retain the anti-scarring and anti-inflammatory properties seen when they are derived from MSCs grown in two dimensions (2D), a study shows. These findings, obtained from treating a mouse model of pulmonary fibrosis…
The experimental oral therapy AMP945, from Amplia Therapeutics, is as effective as the approved therapy Ofev (nintedanib) at reducing tissue scarring, or fibrosis, in a mouse model of idiopathic pulmonary fibrosis (IPF), the company said. In addition, findings from an already completed Phase 1 trial in healthy…
Almost 30 hours after my bilateral lung transplant, it was time for me to be extubated and take my first solo breath with my new lungs. My wife, Susan, was at my bedside, along with several nurses. In a video of that day last July, you can hear Susan ask…
The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in Cleveland, Ohio. The event, which brings together the rare disease community, will take place at the InterContinental Cleveland Conference…
This time a year ago was very different for my wife, Susan, and me. My idiopathic pulmonary fibrosis (IPF) was no longer stable, but progressing. Susan was confident I wouldn’t make it to Christmas. Upon exertion, I needed over 7 liters per minute (lpm) of supplemental oxygen. Exertion…
